Understanding the genetic changes in a specific type of small cell lung cancer.
Official title: Lineage evolution of a small cell lung cancer epigenomic subtype signified by NKX2-1
Funded at Icahn School of Medicine at Mount Sinai · NIH-11050205 · Data updated 2026-11-12
This study is looking at the genetic changes in small cell lung cancer to find out how it behaves differently and to discover new ways to treat it, which could help patients get more personalized and effective therapies.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Icahn School of Medicine at Mount Sinai NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | December 4, 2024 |
| Project end | November 30, 2029 |
| Funding year | 2025 |
| Award (this year) | $701,538 |
| NIH project number | 1R01CA289009-01A1 |
| Project ID | NIH-11050205 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with small cell lung cancer, particularly those with advanced or metastatic disease.
✕Less likely to help
Patients with non-small cell lung cancer or those without a diagnosis of lung cancer may not receive any benefit from this research.
What this research studies
This research investigates the genetic and epigenetic changes in small cell lung cancer (SCLC), a particularly aggressive form of lung cancer. By analyzing the molecular subtypes of SCLC, the study aims to uncover distinct biological behaviors and potential therapeutic targets. The approach involves large-scale genetic studies and epigenetic profiling to enhance the understanding of SCLC pathogenesis and improve treatment options. Patients may benefit from insights that could lead to more personalized and effective therapies.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment strategies and outcomes for patients with small cell lung cancer.
How similar studies have gone: Previous research has shown promise in identifying genetic changes in lung cancer, but this specific focus on SCLC subtypes is relatively novel.
Where this research is happening
-
Icahn School of Medicine at Mount Sinai
New York, United States Active
Researchers
- Principal investigator: Watanabe, Hideo — Icahn School of Medicine at Mount Sinai
- Study coordinator: Watanabe, Hideo
Related research
Other NIH-funded projects on the same topics.
-
ABL kinase signaling and DNA collisions in small cell lung cancer
A drug target study in small cell lung cancer explores how blocking ABL kinase affects conflicts between transcription and DNA replication, which could influence tumor growth and survival.
-
XRN1 as a potential therapy target in lung cancer
A scientist-led program will study a cellular gene called XRN1 to see if turning it off can help treat non-small cell lung cancer.
-
Intermittent fasting with PD-1 inhibitors for non-small cell lung cancer
This grant tests whether a fasting-mimicking diet can boost the effectiveness of PD-1 inhibitors for people with non-small cell lung cancer.
-
Targeting STRAP to curb NSCLC spread with nanoparticle therapy
Aimed at non-small cell lung cancer, this grant tests how blocking a protein called STRAP with nanoparticles could slow cancer spread and make chemotherapy work better.
-
Modeling tumor differences to guide new treatments for resistant small cell lung cancer
A study aims to understand why some small cell lung cancer tumors resist treatment and use those insights to develop new targeted therapies.
-
TP53-mutant NSCLC: how epigenetic viral mimicry could boost immune therapy
A research grant exploring how p53 mutations in non-small cell lung cancer affect responses to a viral mimicry-based epigenetic therapy, with the goal of improving immune therapy outcomes for patients.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.